Shareholders endorse name change to Cardiac Biotech Solutions, Inc. subject to regulatory approval
LAS VEGAS, NV / ACCESSWIRE / March 19, 2024 / CB Scientific, Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the company successfully concluded its Annual Meeting of Stockholders ("Annual Meeting") on Thursday, March 14, 2024 as planned. Votes representing approximately 66.87% of the total eligible shares were counted, and each of the 4 proposals on the agenda passed by a wide margin. Efforts to implement certain matters including updating the Company's Bylaws and changing the name of the Company to Cardiac Biotech Solutions, Inc., are expected to commence immediately.
"We were pleased that an overwhelming majority of our shareholders exhibited ample trust and confidence in management's recommendations to vote accordingly," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "Each of these actions are intended to position the Company for future success, and we now plan to continue aggressively pursuing our previously stated business objectives without delay."
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provides improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: [email protected]
Investor Inquiries: [email protected]
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.